Tempus AI Reports Strong Q2 2025 Results, Driven by AI-Powered Genomics and Data Services
7 Sources
[1]
Tempus AI Gears Up For Q2 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts - Tempus AI (NASDAQ:TEM)
Tempus AI, Inc. TEM will release earnings results for the second quarter before the opening bell on Friday, Aug. 8. Analysts expect the Chicago, Illinois-based company to report a quarterly loss at 25 cents per share, versus a year-ago loss of 63 cents per share. Tempus AI projects to report
[2]
Earnings Outlook For Tempus AI - Tempus AI (NASDAQ:TEM)
Tempus AI TEM is gearing up to announce its quarterly earnings on Friday, 2025-08-08. Here's a quick overview of what investors should know before the release. Analysts are estimating that Tempus AI will report an earnings per share (EPS) of $-0.34. The announcement from Tempus AI is eagerly
[3]
Where Tempus AI Stands With Analysts - Tempus AI (NASDAQ:TEM)
Ratings for Tempus AI TEM were provided by 5 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months. Analysts
[4]
Why Is Tempus AI Stock Soaring Friday? - Tempus AI (NASDAQ:TEM)
Tempus AI Inc. TEM reported second-quarter financial results Friday. The AI-focused precision medicine and patient care company reported a second-quarter adjusted loss of 22 cents per share, beating analyst estimates for a loss of 24 cents per share. Tempus AI reported quarterly revenue of
[5]
Tempus AI (TEM) Q2 Revenue Surges 90%
Tempus AI (TEM 5.78%), a technology company that applies artificial intelligence to precision diagnostics and healthcare data, reported its Q2 2025 earnings on August 8, 2025. The period was marked by rapid growth and strong performance across its genomics and data services businesses. Revenue
[6]
Why Tempus AI Stock Jumped Today | The Motley Fool
Second-quarter results arrived with numbers that caused investors to feel increasingly bullish. The stock of Tempus AI (TEM 3.63%) gave back some of its gains after surging early in Friday's trading, but it still ended the daily session solidly in the green. The healthcare artificial intelligence
[7]
Tempus AI: Q2 Earnings Mark a Turning Point in AI-Powered Healthcare Strategy | Investing.com UK
Tempus AI Inc (NASDAQ:TEM) has released its financial results for the second quarter of 2025, showcasing significant growth in revenue and improved adjusted EBITDA. The company is also optimistic about its future financial performance, as reflected in its updated guidance. Tempus AI, Inc. has
Share
Copy Link
Tempus AI, a leader in AI-driven precision medicine, reported impressive Q2 2025 results with revenue surging 89.6% year-over-year. The company raised its full-year outlook and is nearing adjusted EBITDA profitability, showcasing the growing impact of AI in healthcare.
Tempus AI Reports Strong Q2 2025 Financial Results
Tempus AI Inc. (NASDAQ: TEM), a leading AI-driven precision medicine company, announced its second-quarter 2025 financial results on August 8, showcasing significant growth and improved profitability
1
2
4
.Revenue Surge and Earnings Beat
The company reported Q2 revenue of $314.64 million, representing an impressive 89.6% year-over-year increase and surpassing analyst estimates of $296.85 million
4
. Tempus AI's adjusted loss per share narrowed to $0.22, beating expectations of a $0.24 loss4
.
Source: Motley Fool
Genomics and Data Services Drive Growth
Tempus AI's genomics segment, which includes oncology and hereditary testing, contributed $241.8 million in revenue, growing 115.3% year-over-year
4
. The company delivered over 212,000 next-generation sequencing (NGS) tests, reflecting a 30% increase in clinical volumes4
.Data and services revenue reached $72.8 million, up 35.7% from the previous year, driven by the company's Insights (data licensing) product, which grew 40.7%
4
.Margin Improvement and Path to Profitability
Gross margins (GAAP) improved significantly, climbing to 62.2% from 45.2% in Q2 2024
5
. The company's adjusted EBITDA loss narrowed to $5.6 million, compared to a $31.2 million loss in the same quarter last year4
.AI-Driven Product Advancements
Tempus AI continues to leverage its vast database of over 350 petabytes of clinical and molecular data to develop AI-enabled diagnostics
5
. Recent product launches include:- Tempus Next: An AI-powered clinical decision support tool for oncology
5
- Tempus One: An AI clinical assistant integrated with electronic health records
5
- Tempus xM: A liquid biopsy test for monitoring minimal residual disease in advanced cancer
5
Strategic Partnerships and Database Expansion
The company's database now comprises over 40 million patient records, with more than 4,500 healthcare system integrations
5
. Tempus AI recently secured a $200 million, three-year agreement with AstraZeneca and Pathos to build a large AI model for oncology5
.Related Stories
Raised Outlook for 2025
Following the strong Q2 performance, Tempus AI increased its full-year 2025 revenue guidance to approximately $1.26 billion, representing 82% annual growth
4
. The company also reaffirmed its expectation of achieving $5 million in adjusted EBITDA for the full year, marking a significant improvement of $110 million over 20244
.Regulatory Milestones
Source: Benzinga
In July 2025, Tempus AI received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its ejection fraction software, which uses AI to identify patients with potential left ventricular ejection fraction issues
4
.Financial Position
Tempus AI ended the quarter with $293.0 million in cash and marketable securities, an improvement of around $70 million from the previous quarter
4
. The company also completed a $750 million convertible notes offering shortly after Q2, enhancing its financial flexibility for future AI investments5
.As Tempus AI continues to expand its AI-driven precision medicine platform, investors and industry observers will be closely watching the company's progress in scaling its genomics testing volume, launching new AI products, and securing additional partnerships and regulatory approvals to drive future growth.
References
Summarized by
Navi
[5]
Related Stories
Tempus AI Stock Soars on Collaboration with Follicular Lymphoma Institute, Attracts Major Institutional Investors
14 Feb 2025•Technology
Tempus AI Stock Soars 108% in 2025 Amid Mixed Q4 Earnings and Future Prospects
25 Feb 2025•Business and Economy
Tempus AI Stock Surges Amid Options Frenzy and Nancy Pelosi's Investment
01 Feb 2025•Business and Economy
Recent Highlights
1
AI Hallucination Nearly Sparked US Military Confrontation With Chinese Ship in Middle East
Technology
2
OpenAI AI Agent Hacks Australian Government Healthcare Website in First-of-Its-Kind Breach
Technology
3
AI leaders warn UN Security Council of existential risks to humanity, call for global safeguards
Policy and Regulation
Recent Highlights
Today's Top Stories
Don’t drown in AI news. We cut through the noise - filtering, ranking and summarizing the most important AI news, breakthroughs and research daily. Follow topics that matter to you and stay ahead.
